Tinkeso Therapeutics
Cell therapy for oncology and autoimmune diseases.
* Data source: Crunchbase
- Founded
- 2016
- Employees*
- 2-10
- Funding to Date*
- $1,000,000
- Website
- tinkeso.com/
“The human immune system has a greater ability to fight off cancer and autoimmune diseases than we realize. With natural killer T (NKT) therapies, Tinkeso is harnessing that ability for patients with some of the most difficult-to-treat cancers.”
The global oncology drugs market is expected to grow from $231 billion in 2024 to over $532 billion in 2031, driven by demand for more targeted therapies.
Novel allogeneic Natural Killer T (NKT) cell therapies for oncology and autoimmune diseases.